Table 8

Endoscopically detected ulcers in patients treated for arthritis, with and without aspirin

Number of

Incidence of events (%)


Outcome/ comparisons

Celecoxib daily dose

Comparator and daily dose

Trials

Patients

Celecoxib

Comparator

Relative riska (95% CI)

NNTpb or NNHc (95% CI)


Analysis irrespective of aspirin use


Celecoxib v placebo

Any

Placebo

2

1,737

3.9

2.2

1.8 (0.89–3.6)

Celecoxib (200/400) v NSAID

200–400 mg

NSAID to maximum daily

6

4,135

4.6

16.3

0.30 (0.24–0.37)a

8.6 (7.4–10)b

Celecoxib (any dose) v NSAID

Any

NSAID to maximum daily

6

4,565

4.5

16.3

0.29 (0.24–0.36)a

8.4 (7.3–10)b


Analysis without aspirin use


Celecoxib v placebo

Any

Placebo

2

1,537

3.3

1.9

1.8 (0.79–3.9)

Celecoxib (200/400) v NSAID

200–400 mg

NSAID to maximum daily

5

3,053

4.5

17.6

0.28 (0.22–0.36)a

7.6 (6.5–9.1)b

Celecoxib (any dose) v NSAID

Any

NSAID to maximum daily

5

3,440

4.2

17.6

0.28 (0.22–0.36)a

7.5 (6.4–8.9)b


Analysis with aspirin use


Celecoxib v placebo

Any

Placebo

2

200

7.9

4.1

1.7 (0.45–6.3)

Celecoxib (200/400) v NSAID

200–400 mg

NSAID to maximum daily

5

344

10.0

23.8

0.47 (0.27–0.83)a

7.3 (4.6–17)b

Celecoxib (any dose) v NSAID

Any

NSAID to maximum daily

5

387

9.9

23.8

0.48 (0.28–0.83)a

7.2 (4.7–16)b


aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.

Moore et al. Arthritis Research & Therapy 2005 7:R644-R665   doi:10.1186/ar1704

Open Data